Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)‎”

المؤلفون المشاركون

Yokoyama, Hirokazu
Ebinuma, Hirotoshi
Oikawa, Yoichi
Kikuchi, Masahiro
Shimada, A.
Irie, Junichiro
Itoh, Hiroshi
Tomita, Kengo
Saito, Hidetsugu
Hirose, Hiroshi
Kawai, Toshihide
Ojiro, Keisuke
Hirata, Takumi
Hibi, Toshifumi

المصدر

International Journal of Endocrinology

العدد

المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-1، 1ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2014-04-27

دولة النشر

مصر

عدد الصفحات

1

التخصصات الرئيسية

الأحياء

الملخص EN

In the paper, the dosage of telmisartan is incorrect due to a typographical error.

Twelve patients, assigned to telmisartan group, received telmisartan at a dose of 40 mg, not 20 mg, once a day.

The correct sentences should appear as given below.

(1) “Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 40 mg once a day ( n = 12 ) or losartan at a dose of 50 mg once a day ( n = 7 ) for 12 months” in the “Methods” section of the “Abstract.” (2) “Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to the telmisartan (T) group (receiving a standard dose of 40 mg once daily, n = 12 ) or the losartan (L) group (receiving a standard dose of 50 mg once daily, n = 7 )” in Section 2.2.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, A.& Kikuchi, Masahiro…[et al.]. 2014. Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”. International Journal of Endocrinology،Vol. 2014, no. 2014, pp.1-1.
https://search.emarefa.net/detail/BIM-1036453

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Hirata, Takumi…[et al.]. Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”. International Journal of Endocrinology No. 2014 (2014), pp.1-1.
https://search.emarefa.net/detail/BIM-1036453

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, A.& Kikuchi, Masahiro…[et al.]. Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”. International Journal of Endocrinology. 2014. Vol. 2014, no. 2014, pp.1-1.
https://search.emarefa.net/detail/BIM-1036453

نوع البيانات

مقالات

لغة النص

الإنجليزية

رقم السجل

BIM-1036453